Followers | 17 |
Posts | 4234 |
Boards Moderated | 0 |
Alias Born | 04/13/2016 |
Monday, May 22, 2017 10:03:07 PM
My sense of the numerous posts of late is that very few people have changed their minds as a function of the discussion. I confess to a little 'post fatigue' by seeing largely the same issues rehashed on both sides of the fence. I'm hoping we might all just move on.
Two more issues. First, TRUTH raised the issue of additional funding for Notre Dame, which apparently has a near-term end date. He speculated that KBLB might be switching to a different scientific team. I'm going to suggest a different direction: I believe the recent rounds of genetic modifications, leading to four new strains we have not heard much of, weren't as successful as KBLB hoped. KBLB is therefore paying for an additional round of genetic insertions. The extension is short-term because that is all KBLB can pay for at this point.
Again I call attention to the speculative nature of my claim. I don't have any evidence in support of this idea.
My final issue is something that I didn't see in the latest quarterly report, but may have overlooked. Did they report expenditures to cover travel to Vietnam? I don't recall seeing those charges listed. Also, I've not seen much in the way of operations for their silkworm rearing facility. Do we know how much this is costing them?
Unless I overlooked these expenses, I'm guessing that Kim Thompson paid for these out-of-pocket. That could be a part of the $2m+ he is owed on the books.
If so, it speaks to Mr. Thompson's unwillingness to dilute stock through sales to Calm Seas and also his confidence that KBLB will turn profitable soon.
Any thoughts? I'm not as good at reading financial reports as others on this board.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM